Novel gene target shows promise for bladder cancer detection and treatment

July 24, 2013

Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.

The study, published in the journal Clinical Cancer Research, was a collaborative effort between Paul B. Fisher, M.Ph., Ph.D., who originally discovered the mda-9/syntenin gene, and Santanu Dasgupta, Ph.D., an expert in research. Through cell cultures and mouse models of human bladder cancer, the researchers demonstrated that mda-9/syntenin helps to regulate bladder and metastasis. They also showed that an increase in the gene's expression correlates with disease progression, making it a promising target for detecting and monitoring the growth and metastasis of bladder cancer. In addition, suppressing mda-9/syntenin expression resulted in a substantial decrease in cancer growth and its ability to spread.

"Currently, there are no biomarkers that can accurately predict bladder , or monitor its progression," says Fisher, Thelma Newmeyer Corman Endowed Chair in Cancer Research and co-leader of the Cancer Molecular Genetics program at VCU Massey, chairman of the Department of Human and Molecular Genetics at VCU School of Medicine and director of the VCU Institute of Molecular Medicine (VIMM). "Our findings could assist in the development of innovative ways to detect, monitor and treat bladder cancer."

The team discovered that mda-9/syntenin regulates bladder by impacting (EGFR) signaling. EGFR is located on the surface of bladder and plays a part in a variety of mechanisms that contribute to cell proliferation, the growth of new blood vessels, cell migration and resistance to apoptosis – a form of cell suicide. The researchers showed that mda-9/syntenin physically binds to EGFR and disrupts a variety of processes that help keep cancer in check.

Fisher has previously shown that mda-9/syntenin is overexpressed in a variety of cancers and is a key contributor to metastasis in melanoma. Fisher and Dasgupta plan to continue exploring the role of mda-9/syntenin in the development of bladder cancer. Future studies will utilize animal models to determine the mechanisms by which the gene helps to initiate the disease in order determine the point at which the gene's expression indicates a positive cancer diagnosis.

"Bladder cancer is often diagnosed through an invasive procedure that involves inserting a flexible camera through the urethra, which may cause some people to delay testing and, in turn, treatment," says Dasgupta, member of the Cancer Molecular Genetics program at VCU Massey, assistant professor in the VCU Department of Human and Molecular Genetics and VIMM member. "We hope that our studies will lead to new, less invasive ways to detect and treat bladder cancer and, ultimately, fewer deaths."

Explore further: Research breakthrough could halt melanoma metastasis

More information: Clinical Cancer Research Doi: 10.1158/1078-0432.CCR-13-0585

Related Stories

Research breakthrough could halt melanoma metastasis

November 14, 2012
In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 ...

Scientists discover how deadly skin cancer spreads into other parts of the body

January 3, 2013
After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the ...

Targeted viral therapy destroys breast cancer stem cells in preclinical experiments

June 24, 2013
A promising new treatment for breast cancer being developed at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) has been shown in cell culture and in animal models to ...

Little molecule makes big difference in bladder cancer metastasis

April 9, 2013
In order to kill, bladder cancer must metastasize, most commonly to the lung – what are the differences between bladder cancers that do and do not make this deadly transition? Research presented by the Director of the University ...

Scientists develop mouse model that could lead to new therapies for liver cancer

July 6, 2012
Researchers have created the first mouse model demonstrating the role of a cancer promoting gene, Astrocyte elevated gene-1 (AEG-1), in hepatocellular carcinoma, or liver cancer. The mouse model represents a critical step ...

The link between genes and cancer

June 18, 2013
(Medical Xpress)—When people think about genes and their relationship to cancer, most probably think about a person's hereditary cancer risk, especially after Angelina Jolie's recent news about her inherited breast and ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.